Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5399-5407

  MacCallum, David E ^a   Melville, Jean ^a   Frame, Sheelagh ^a   Watt, Kathryn ^a   Anderson, Sian ^a   Gianella Borradori, Athos ^a   Lane, David P ^a   Green, Simon R ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLIN T1; GENE PRODUCT; MESSENGER RNA; PROTEIN MCL 1; RNA POLYMERASE II; ROSCOVITINE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PHASE; CELL DEATH; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; DEPHOSPHORYLATION; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH;

APOPTOSIS; CELL LINE, TUMOR; DICHLORORIBOFURANOSYLBENZIMIDAZOLE; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PURINES; RNA POLYMERASE II; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 20444477948     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0233     Document Type: Article

References (52)

1. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313.
2. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 2000;100:71-8.
3. Nurse PM. Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep 2002;22:487-99.
4. Kimura K, Hirano M, Kobayashi R, Hirano T. Pbosphorylation and activation of 13S condensin by Cdc2 in vitro. Science 1998;282:487-90.
5. Bregman DB, Pestell RG, Kidd VJ. Cell cycle regulation and RNA polymerase II. Front Biosci 2000;5:D244-57.
6. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002;190:160-9.
7. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. HIV-I Tat interaction with RNA polymerase II exterminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 2002; 277:33922-9.
8. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
9. Fischer PM, Gianella-Borradori A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2003;12:955-70.
10. 1 phase by specific inhibition of CDK2 kinase activity. Exp Cell Res 1998; 245:8-18.
11. Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001;60:785-9.
12. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001;20:3206-16.
13. Sirri V, Hernandez-Verdun D, Roussel P. Cyclin-dependent kinases govern formation and maintenance of the nucleolus. J Cell Biol 2002;156:969-81.
14. David-Pfeuty T, Nouvian-Dooghe Y, Sirri V, Roussel P, Hernandez-Verdun D. Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells. Oncogene 2001; 20:5951-63.
15. Whittaker SR, Walton MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004;64:262-72.
16. Kuehl WM, Bergsagel PL. Multiple myeloma: evoking genetic events and host interactions. Nat Rev Cancer 2002;2:175-87.
17. Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504-11. Epub 2003 Aug 28.
18. Voss JD, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 2002;21:6848-57.
19. Munshi NC, Hideshima T, Carrasco D, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004;103: 1799-806.
20. Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003;13:115-23.
21. Yang T, Buchan HL, Townsend KJ, Craig RW. Mcl-1, a member of the Bcl-2 family, is induced in response to signals for cell differentiation or death, but not signals for proliferation. J Cell Physiol 1996;166:523-36.
22. Zhang B, Gojo I, Fenton RG. Myoloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002;99:1885-93.
23. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein in human myeloma cells. Blood 2002;100:194-9.
24. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl1. Clin Cancer Res 2002; 8:3527-38.
25. Michels J, O'Neill JW, Dallman CL, et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene 2004;23:4818-27.
26. Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 2004;34:3156-64.
27. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
28. Giles RV, Spiller DG, Gryzbowski J, Tidd DM. Enhanced antisense effects resulting from an improved: streptolysin-O protocol for oligodeoxynucleotide delivery into human leukaemia cells. Nucleosides and nucleotides 1997;16:1155-63.
29. Zhu Y, Pe'ery T, Peng J, et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 1997;11:2622-32.
30. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 2004;3:1537-42.
31. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:RESEARCH0041.
32. Dubois MF, Nguyen VT, Beller S, Bensaude O. Inhibitors of transcription such as 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole and ioquinoline sulphonamide derivatives (H-8 and H-7) promote dephosphorylation of the carboxyl-terminal domain of RNA polymerase II largest subunit. J Biol Chem 1994;269:13331-6.
33. Li X, Darzynkiewicz Z. Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif 1995;28:571-9.
34. Bregman DB, Du L, van der Zee S, Warren SL. Transcription-dependent redistribution of the large subunit of RNA polymerase II to discrete nuclear domains. J Cell Biol 1995;129:287-98.
35. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J 1991; 10:4279-90.
36. 1-S cyclin-dependent kinases. J Biol Chem 1997;272:12738-46.
37. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997;75:337-49.
38. Olson DC, Marechal V, Momand J, et al. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993;8:2353-60.
39. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7.
40. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci U S A 1998;95:195-200.
41. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
42. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003;100:9946-51.
43. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26:199-213.
44. Hirose Y, Manley JL. RNA polymerase II and the integration of nuclear events. Genes Dev 2000;14: 1415-29.
45. Chao SH, Fujinaga K, Marion JE, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000;275:28345-8.
46. Yankulov K, Yamashita K, Roy R, Egly JM, Bentley DL. The transcriptional elongation inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. J Biol Chem 1995; 270:23922-5.
47. Kaldis P. The cdk-activating kinase (CAK): from yeast to mammals. Cell Mol Life Sci 1999;55:284-96.
48. Schubert KM, Duronio V. Distinct roles for extracellular-signal-regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis. Biochem J 2001;356:473-80.
49. Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci 1996;21: 267-71.
50. Teoh G, Tai YT, Urashima M, et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 2000;95:1039-46.
51. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
52. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004;64:3653-60.